zoeti spun lead global manufactur medic vaccin
livestock revenu companion anim revenu
result solid guidanc bracket street estim fx
bp neg impact continu fairli harsh
headwind gross margin expect improv rang
number move part affect earn growth
higher tax rate higher interest expens greater spend etc think ztss
underli fundament remain good shape year
execut invest increas estim revis
ep estim resid near lower end guidanc rang think
upsid versu estim could come greater share repurchas activ
maintain buy rate bump price target
nutshel adjust ep higher consensu
estim revenu increas
modestli higher consensu estim
organ oper growth driven price volum
fx creat bp headwind quarter companion anim
oper revenu growth driven growth
intern growth livestock sale increas oper vs
estim driven growth intern growth
gross margin decreas bp vs estim
neg impact fx abaxi contribut inventori charg
new product continu drive signific growth invest
pipelin encourag organ oper growth came
volum includ key dermatolog product apoquel
cytopoint came new product includ simparica
manag clearli expect invest pipelin year
area like monoclon antibodi therapeut pain felin allergi
zoeti complet dossier file fda think could
first market triple-combo oral flea tick heartworm medic
call simparica trio time approv fda remain uncertain
guidanc introduc follow solid result guidanc
introduc follow rang detail follow page
page
period except per share revenueadj epsrevenueadj epsrevenueadj epsrevenueadj previou revis compani data factset estim craig-hallum capit group llc guidancelowhighrevenu revenue tax ni oper compani report
revenu varianc detail
livestock growth modestli better expect total livestock
revenu decreas oper growth off-set fx
headwind slightli ahead estim
constant currenc basi main driver livestock growth
poultri fish swine increas cattl
grew oper
increas higher estim
oper growth main driver fx
bp headwind constant currenc basi sale dog cat
product increas equin product sale increas
zoetiss dermatolog franchis continu drive strong growth
sale simparica note
apoquel apoquel sale increas consist
 intern
sale year apoquel revenu grew y/i
deriv
come intern sale
cytopoint sale zoetiss monoclon antibodi atop
dermat increas y/i driven
sale intern sale
cytopoint sale increas cross blockbust
threshold annual sale cytopoint revenu
increas intern sale
blockbust revenu y/i
simparica revenu increas driven
sale revenu
ztss intern revenu decreas y/i
lower estim oper
growth in-lin estim fx neg
bp impact wors estim
livestock revenu decreas
lower estim driven
oper growth in-lin estim fx
bp headwind livestock sale driven
page
varianc varianc except per share c-h estimate con actualto c-h estimate c-h estimate revenu better expect partial due full quarter contribut fromy/i well better expect companion anim livestock growthu companion abaxi companion anim growth driven growth y/i product sale sale growth simparicau livestock revenu better expect due increas sale premiumy/i continu suppli contract competitor cattl vaccineern oper revenu increas driven strong companion anim sale growthy/i oper greater headwind intern sale due devalu brazilian realfx companion companion anim sale grew oper basi driven contributiony/i abaxi parasiticid growth simparica dog stronghold cat oper sale across dermatolog portfolio livestock sale grew oper driven poultri swine fish whiley/i sale rel flat poultri growth came emerg market egyptoper indonesia swine growth driven recent launch vaccinescontract manufactur better expect due inclus abaxi human dxy/i oper revenu increas abaxi ad revenu lead toy/i cc growth driven price came volum oper volum growth key dermatolog simparica new productssourc compani data factset estim craig-hallum capit group llc
growth poultri swine fish product cattl
rel flat also saw growth poultri product
emerg market like egypt indonesia swine busi
benefit recent launch two vaccin suvaxyn pcv
combo prr vaccin europ compani
aquacultur busi grew due share gain pd vaccin
 norway livac sr vaccin chile
companion anim revenu increas y/i
lower estim
driven oper growth vs estim
partial off-set bp fx headwind strong companion
anim growth driven contribut abaxi
increas sale simparica dog stronghold cat
well increas sale apoquel cytopoint
countri perspect oper cc growth strongest
china canada emerg market
experienc weaker growth germani australia
japan despit continu currenc devalu brazil
guidanc in-lin street estim zoeti provid
guidanc includ revenu adjust ep
oper revenu growth expect
organ growth exclud contribut abaxi expect
in-lin prior expect
ep beat lower tax adjust ep
higher consensu tax rate lower expect due
 tax reform discret item quarter addit gross
margin lower expect due fx abaxi
contribut full quarter inventori write-off said
zoeti inc page
otherothertot million australiabrazilcanadachinafr germani italyjapanmexicospainuk compani report craig-hallum capit guidanceupd million except per share fy oper cost sale sg interest expens andoth tax rate adj dilut net signific item andacquisition-rel dilut compani data factset estim chlm estim
manag suggest gross margin good gaug expect
run-rat gross margin guid
compani data craig-hallum capit group llc estim
revenu speci continu reflect strong growth companion anim
product like apoquel cytopoint simparica driven dog cat
revenu percent revenu year ago
sale cattl product grew oper cattl still account
total revenu swine follow poultri
sale fish product continu grow nice still account
zoeti inc page
quarterli i/ varianceactualc-h estimate variancevari million except per in-lin revenu driven oper growth includ growth chang oper growth intern businesschang gross margin driven greater fx headwind abaxi acquisit inventorygross gross margin expect expand spend higher due invest monoclon antibodi chronic pain amort pipelin programsoth oper oper oper expens higher due debt offer fund abaxi acquisitionincom rate lower expect due favor impact tax reform discret tax recogn tax rate expect net incom attr incom attribut net incom increas oper primarili due strong top-lin growthnet lower effect tax ratedilut ebitda analysi oper incom attr
increas price target base ev/ebitda multipl
ebitda estim project net debt
share outstand price target also support appli price-to-earnings multipl
ep estim valuat support
long-term discount cash flow dcf valuat analysi use termin growth rate
wacc
believ invest zoeti involv follow risk
increas restrict ban use antibiot use growth promot
livestock fda work phase-out use medic import antibacteri
anim feed growth promot chang produc behavior increas regul
could advers impact zoetiss antibacteri product sale
lead chang underli market demand product
chang util product relat protein consumpt chang
consum spend habit diet protein consumpt could advers effect
zoeti busi
infecti diseas outbreak variou infecti diseas avian flu swine flu
etc could lead cull herd reduct use product
cash pay busi therefor chang economi input cost commod
price could neg impact produc abil buy product
industri consolid increas competit continu consolid
anim health industri could lead increas competit result price pressur
could neg impact margin profit
foreign currenc fluctuat approxim zoeti busi deriv
outsid creat foreign currenc risk
zoeti inc page
page
zoetiscraig-hallum capit groupincom statement mm except per share kevin ellich oper oper oper tax net incom attr non-controlling incom attribut ebitda analysi oper incom attribut non-controlling oper incom attribut compani report craig-hallum capit group llc estimatesfebruari requir disclosur
